Fig. 2From: Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancerIntratumor heterogeneity of pathologic response to neoadjuvant anti-PD-1 treatment: different responses of tumour cell subclones in the same tumour bed. cPR, complete pathologic response; pPR, partial pathologic response; nPR, no pathologic response; LNMCa, lymph node metastatic carcinomaBack to article page